Hyperkalemia Treatment Market by Product Type | Global Industry Forecast, 2032
Hyperkalemia Treatment Market by Type (Patiromer, Sodium Zirconium Cyclosilicate), Application (Hospital Pharmacy, Retail Pharmacy), and Region (North America, Europe, Asia Pacific, South America, Middle East and Africa), Global trends and forecast from 2022 to 2032
Categories: Food & Beverages
Format : 
Hyperkalemia Treatment Market Overview
Hyperkalemia is a condition that is a significance of higher than normal levels of a substance named potassium in the blood. Digging deeper into its etiology, Hyperkalemia is definite as a serum of plasma that constitutes potassium levels on higher sides, usually higher than 5.0 mEq/L to 5.5 mEq/L. Higher levels of potassium can prove to be life-threatening in some instances leading to cardiac arrhythmias, muscle weakness or paralysis.
The treatment of Hyperkalemia is based on physical examinations, blood tests, urinalysis, electrocardiogram tests and other such tests conducted for proper information of the cause of the condition and patient’s state. However, the treatment should also focus on the effectiveness and ability of the treatment by which they lower down the serum potassium levels along with a watchful eye on their side effects. The new drugs for Hyperkalemia need to be tailor-made as per the individuals for the best outcomes.
As per the scope of this report, hyperkalemia (HK), a condition of elevated serum potassium, arises from disturbances to potassium homeostasis inside the body.? Factors such as the growing prevalence of hyperkalemia, increasing focus on research and development, and an increasing amount of strategic alliances among major market players are anticipated to drive the market growth.
The hyperkalemia treatment market is poised to grow at a CAGR of 16.78% over the forecast period for market value of USD 803.17 million[2022-2032]
Increase in prevalence rates of chronic hyperkalemia is credited to increase in the global geriatric population. Aging population and advancement in medical technology are projected to contribute to the rise in frequency of heart failure and chronic kidney diseases. Consequently, a larger pool of patients is likely to be at risk of hyperkalemia.
Instance Developments
PARIS, March 15, 2022. Sanofi and Blackstone (NYSE: BX) announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma (MM). If successful, BXLS will be eligible to receive royalties on future subcutaneous sales. The pivotal study for the subcutaneous formulation is expected to begin in the second half of 2022.
GALLEN, Switzerland, December 21, 2021-Vifor Pharma announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa®in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.
18 May 2018--The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia,1a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases. The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take common medications for heart failure (HF), such as renin-angiotensin-aldosterone system (RAAS) inhibitors, which can increase potassium in the blood.
Hyperkalemia Treatment Market Scope:
| Report Data | Hyperkalemia Treatment Market |
| Hyperkalemia Treatment Market Size 2022 | USD 803.17 million |
| Hyperkalemia Treatment Market CAGR 2022 - 2029 | 16.78% |
| Hyperkalemia Treatment Market Analysis Period | 2022 - 2032 |
| Hyperkalemia Treatment Market Base Year | 2021 |
| Hyperkalemia Treatment Market Forecast Data | 2022 - 2032 |
| Segments Covered | By Type, By Application, And by Regions |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Vifor Pharma, Astrazeneca, Sanofi, CMP Pharma, Belcher Pharmaceuticals |
| Report Coverage | Market Drivers, Market Trends, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Key market Segments | Market by Type Patiromer Segment by Distribution Channel Hospital Pharmacy |
Frequently Asked Questions
What is the future market value of the Hyperkalemia Treatment Market?
The current market value for Hyperkalemia Treatment Market is expected USD 803.17 million by 2032
What is the CAGR of the Market?
The Hyperkalemia Treatment Market is to grow at a CAGR of 16.78% during the forecast by 2032.
What is the Market segment?
On the basis of type, the Hyperkalemia Treatment Market is segmented into Patiromer, Sodium Zirconium Cyclosilicate
Who are the key players operating in the Hyperkalemia Treatment Market?
The major players operating in the Hyperkalemia Treatment Market are Vifor Pharma, Astrazeneca, Sanofi, CMP Pharma, Belcher Pharmaceuticals
Base Year:2021
Historical Data:2017-2022
No of Pages:119
Select Licence Type
Single User
Multi User
Corporate User
Only one user can access the report. It cannot be printed or shared. Delivery in online PDF.
US $ 1499
Multiple users can access the report. It cannot be printed or shared. Delivery in online PDF.
US $ 3499
The entire organization can use the report. It can be printed and shared. Delivery in PDF and Excel. Free update of the report after 1 year.
US $ 5499
Need a Discount? Get in touch with us for special pricing
Connect with our sales team
Email: [email protected]